|Elexacaftor||Cystic fibrosis transmembrane conductance regulator (CFTR) corrector|
|Ivacaftor||Chloride channel opener|
Elexacaftor/ivacaftor/tezacaftor, sold under the brand name Trikafta, is a combination medication used in those that have cystic fibrosis with a f508del mutation. It is made up of a combination of elexacaftor, ivacaftor, and tezacaftor.
A phase III trial showed people treated with elexacaftor/ivacaftor/tezacaftor improved in FEV1 at four weeks with sustained improvement at 24 weeks. Rate of pulmonary exacerbation was 63% lower and a sweat chloride concentration that was 41.8 mmol/L lower.
Society and culture
Elexacaftor/ivacaftor/tezacaftor is a combination tablets containing elexacaftor 100 mg, tezacaftor, 50 mg and ivacaftor 75 mg. It is sold together with ivacaftor 150 mg tablets with which it is used.
Trikafta is approved in the United States for people 12 years and older with cystic fibrosis who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which is estimated to represent 90% of the cystic fibrosis population.
The U.S. Food and Drug Administration (FDA) granted the application priority review, in addition to fast track and breakthrough therapy designation. Trikafta also received orphan drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases. The drug's manufacturer Vertex Pharmaceuticals will receive a rare pediatric disease priority review voucher for having developed this therapy.
- "Trikafta (elexacaftor, ivacaftor and tezacaftor) Patient Information". Drugs.com. October 23, 2019. Archived from the original on October 30, 2019. Retrieved November 13, 2019.
- "FDA approves new breakthrough therapy for cystic fibrosis". U.S. Food and Drug Administration (FDA) (Press release). October 21, 2019. Archived from the original on November 13, 2019. Retrieved November 13, 2019. This article incorporates text from this source, which is in the public domain.
- "Drug Trials Snapshots: Trikafta". U.S. Food and Drug Administration (FDA). October 31, 2019. Archived from the original on November 20, 2019. Retrieved November 20, 2019. This article incorporates text from this source, which is in the public domain.
- Maddipatla, Manojna; O'Donnell, Carl (October 21, 2019). "Vertex prices cystic fibrosis combo treatment at $311,000-per-year". Reuters. Retrieved October 23, 2019.
- Middleton PG, Mall MA, Dřevínek P, et al. (VX17-445-102 Study Group) (October 2019). "Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele". N. Engl. J. Med. 381 (19): 1809–19. doi:10.1056/NEJMoa1908639. ISSN 0028-4793. PMID 31697873.
- Taylor-Cousar JL, Mall MA, Ramsey BW, et al. (April 2019). "Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles". ERJ Open Res. 5 (2): 00082–2019. doi:10.1183/23120541.00082-2019. PMC 6571452. PMID 31218221.
- Clinical trial number NCT03525444 for "A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)" at ClinicalTrials.gov
- "Trikafta- elexacaftor, tezacaftor, and ivacaftor kit prescribing information". DailyMed. October 29, 2019. Retrieved November 20, 2019.
|This pharmacology-related article is a stub. You can help Wikipedia by expanding it.|